Oncology Institute, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the three months ended September 30, 2025, Yale Podnos, an officer of the Company, adopted a Rule 10b5-1 trading plan as of August 26, 2025 providing for the sale of up to an aggregate amount of 46,903 shares of common stock during the period until September 30, 2026. This trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934 and our policies regarding transactions in our securities.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.